Bain Capital, LP is one of the world’s leading private multi-asset alternative investment firms with approximately $95 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. We leverage our shared platform to capture cross-asset class opportunities in strategic areas of focus. With offices on four continents, our global team aligns our interests with those of our investors for lasting impact.

Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact [email protected].

05.22.18

Share this page

Bain Capital Community Partnership Serves as Signature Sponsor for 36th Annual JDRF One Night Gala

On May 12, JDRF held its 36th annual One Night Gala in Boston with Bain Capital Community Partnership as the Signature Sponsor. The event raised a record-breaking $2.5 million to fund research into treating, preventing and curing type-1 diabetes (T1D). Honorees for the night were Rebecca and Bill Power, and the Nancy Jones Diabetes Champion Award was presented to Semma Therapeutics (Co-Founder and Vice President Felicia Pagliuca was there to accept).

The year's successful gala continues Bain Capital's long history of support for JDRF. Bain Capital Private Equity Vice President Colin Motley is on the board of JDRF New England. Sean Doherty was previously on the New England Board for 12 years and was its President. He now serves on JDRF's international board and is the founder and chairman of the T1D Fund, a $70 million venture philanthropy fund investing in early-stage opportunities in the disease. For more than a decade, and each year, Bain Capital partners and employees collectively are by far the largest contributors to JDRF in New England. To date, the Bain Capital community has contributed more than $9 million to JDRF's mission.

JDRF is the leading global organization funding type 1 diabetes (T1D) research. T1D is an autoimmune disease that strikes both children and adults and has nothing to do with diet or lifestyle.  There is nothing you can do to prevent it and, at present, there is no cure. JDRF is working to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications.